Publications by authors named "Fernanda Bocchi Monteiro"
Article Synopsis
- Natalizumab, an anti-integrin monoclonal antibody, is used for autoimmune disorders like multiple sclerosis, but it can rarely cause liver injury, typically presenting as non-severe acute hepatitis after the first or subsequent doses.
- A case study of a 60-year-old woman showed she developed jaundice and severe liver enzyme increases just one day after her first natalizumab infusion, with lab tests revealing signs of drug-induced liver injury.
- The patient was treated with oral prednisone, leading to her progressive recovery and normalization of liver function, highlighting the need for physicians to monitor for early-onset hepatitis in new natalizumab patients, particularly women with multiple sclerosis.
